本帖最后由 老马 于 2012-1-13 21:20 编辑 ' I# f, U, a! m: X
. {; d2 L& [7 q" W
爱必妥和阿瓦斯丁的比较
7 U+ J& T+ } E9 T& s+ Z
: F$ B( Y2 q* b- p) L; e1 whttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 D2 u) L5 l: i6 d1 Q; Y' H8 \
$ j) s! i. P) T, T1 j v, c
# v" l+ O4 Y2 g6 V8 ^2 U
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
$ E. n; O" C8 t7 z) L, _==================================================
# _6 k' O3 ~* A$ R: w5 @7 OOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)- T+ b' i6 i( Q! Z6 I8 Z. H
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
/ E: ?) u/ @% }: I1 C+ `Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
2 S$ g. L* e* }
|